In its Oct. 30 filing with the U.S. Securities and Exchange Commission, PGDx said the final amount of the round, expected to close in the coming weeks, could be higher or lower than the $111.5 million target.
Cancer diagnostics firm Personal Genome Diagnostics (PGDx) has raised $65m in an open equity financing round. It aims to raise a total of $111.5m in the round. The round was led by New York-based venture capital firms Andreessen Horowitz and Greylock Partners, with participation from existing investors including Kleiner Perkins Caufield & Byers, Accel Partners and Lightspeed Venture Partners. Thus far, 12 investors have purchased equity. PGDx already gained $21.4m in a series A funding round in 2015, adding to its previous $2.8m in seed funding.